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Complex IEvidence suggests that mitochondrial metabolism may play a key role in controlling cancer cells life and
proliferation. Recent evidence also indicates how the altered contribution of these organelles to metabolism
and the resistance of cancer mitochondria against apoptosis-associated permeabilization are closely related.
The hallmarks of cancer growth, increased glycolysis and lactate production in tumours, have raised attention
due to recent observations suggesting a wide spectrum of oxidative phosphorylation deﬁcit and decreased
availability of ATP associated with malignancies and tumour cell expansion. More speciﬁcally, alteration in
signal transduction pathways directly affects mitochondrial proteins playing critical roles in controlling the
membrane potential as UCP2 and components of both MPTP and oxphos complexes, or in controlling cells life
and death as the Bcl-2 proteins family. Moreover, since mitochondrial bioenergetics and dynamics, are also
involved in processes of cells life and death, proper regulation of these mitochondrial functions is crucial for
tumours to grow. Therefore a better understanding of the key pathophysiological differences between
mitochondria in cancer cells and in their non-cancer surrounding tissue is crucial to the ﬁnding of tools
interfering with these peculiar tumour mitochondrial functions and will disclose novel approaches for the
prevention and treatment of malignant diseases. Here, we review the peculiarity of tumour mitochondrial
bioenergetics and the mode it is linked to the cell metabolism, providing a short overview of the evidence
accumulated so far, but highlighting the more recent advances. This article is part of a Special Issue entitled:
Bioenergetics of Cancer.IFs, hypoxia-inducible factors;
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Mitochondria are essential organelles and key integrators of
metabolism, but they also play vital roles in cell death and cell
signaling pathways critically inﬂuencing cell fate decisions [1–3].
Mammalian mitochondria contain their own DNA (mtDNA), which
encodes 13 polypeptides of oxidative phosphorylation complexes, 12S
and 16S rRNAs, and 22 tRNAs required for mitochondrial function [4].
In order to synthesize ATP through oxidative phosphorylation(oxphos), mitochondria consume most of the cellular oxygen and
produce the majority of reactive oxygen species (ROS) as by-products
[5]. ROS have been implicated in the etiology of carcinogenesis via
oxidative damage to cell macromolecules and through modulation of
mitogenic signaling pathways [6–8]. In addition, a number of
mitochondrial dysfunctions of genetic origin are implicated in a
range of age-related diseases, including tumours [9]. How mitochon-
drial functions are associated with cancer is a crucial and complex
issue in biomedicine that is still unravelled [10,11], but it warrants an
extraordinary importance since mitochondria play a major role not
only as energy suppliers and ROS “regulators”, but also because of
their control on cellular life and death. This is of particular relevance
since tumour cells can acquire resistance to apoptosis by a number of
mechanisms, including mitochondrial dysfunction, the expression of
anti-apoptotic proteins or by the down-regulation or mutation of pro-
apoptotic proteins [12].
Cancer cells must adapt their metabolism to produce all molecules
and energy required to promote tumour growth and to possibly
modify their environment to survive. These metabolic peculiarities of
cancer cells are recognized to be the outcome of mutations in
oncogenes and tumour suppressor genes which regulate cellular
metabolism. Mutations in genes including P53, RAS, c-MYC, phos-
phoinosine 3-phosphate kinase (PI3K), and mTOR can directly or
through signaling pathways affect metabolic pathways in cancer cells
as discussed in several recent reviews [13–17]. Cancer cells harboring
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such as hypoxia inducing adaptive metabolic alterations which
include glycolysis up-regulation and angiogenesis factor release
[18,19]. In response to hypoxia, hypoxia-induced factor 1 (HIF-1)
[20], a transcription factor, is up-regulated, which enhances expres-
sion of glycolytic enzymes and concurrently it down regulates
mitochondrial respiration through up-regulation of pyruvate dehy-
drogenase kinase 1 (PDK1) (see recent reviews [21,22]). However,
several tumours have been reported to display high HIF-1 activity
even in normoxic condition, now referred to as pseudohypoxia [23–
25]. In addition, not only solid tumours present a changedmetabolism
with respect to matched normal tissues, hematological cell malig-
nancies also are characterized by peculiar metabolisms, in which
changes of mitochondrial functions are signiﬁcant [26–28], therefore
indicating a pivotal role of mitochondria in tumours independently
from oxygen availability.
Collectively, actual data show a great heterogeneity of metabolism
changes in cancer cells, therefore comprehensive cellular and
molecular basis for the association of mitochondrial bioenergetics
with tumours is still undeﬁned, despite the numerous studies carried
out. This review brieﬂy revisits the data which are accumulating to
account for this association and highlights the more recent advances,
particularly focusing on the metabolic and structural changes of
mitochondria.
2. Mitochondria-related metabolic changes of cancer cells
Accumulating evidence indicate that many cancer cells have an
higher glucose consumption under normoxic conditions with respect
to normal differentiated cells, the so-called “aerobic glycolysis”
(Warburg effect), a phenomenon that is currently exploited to detect
and diagnose staging of solid and even hematological malignancies
[27]. Since the initial publication by Otto Warburg over half a century
ago [29], an enormous amount of studies on many different tumours
have been carried out to explain the molecular basis of the Warburg
effect. Although the regulatory mechanisms underlying aerobic and
glycolytic pathways of energy production are complex, making the
prediction of speciﬁc cellular responses rather difﬁcult, the actual data
seem to support the view that in order to favour the production of
biomass, proliferating cells are commonly prone to satisfy the energy
requirement utilizing substrates other than the complete oxidation
of glucose (to CO2 and H2O). More precisely, only part (40 to 75%,
according to [30]) of the cells need of ATP is obtained through the
scarcely efﬁcient catabolism of glucose to pyruvate/lactate in the
cytoplasm and the rest of the ATP need is synthesized in the
mitochondria through both the tricarboxylic acid (TCA) cycle (one ATP
produced each acetyl moiety oxidized) and the associated oxidative
phosphorylation that regenerates nicotinamide- and ﬂavin-dinucleotides
in their oxidized state(NAD+ and FAD). This might be due to the
substrate availability as it was shown in HeLa cells, where replacing
glucose with galactose/glutamine in the culture medium induced
increased expression of oxphos proteins, suggesting an enhanced energy
production from glutamine [31]. As a conclusion the authors proposed
that energy substrate can modulate mitochondrial oxidative capacity in
cancer cells. A direct evidence of this phenomenon was provided a few
years later in glioblastoma cells, in which it was demonstrated that the
TCA cycle ﬂux is signiﬁcantly sustained by anaplerotic alfa-ketoglutarate
produced from glutamine and by acetyl moieties derived from the
pyruvate dehydrogenase reaction where pyruvate may have an origin
other than glucose [32]. The above changes are the result of genetic
alteration and environmental conditions that inducemany cancer cells to
change their metabolism in order to synthesize molecules necessary to
survive, grow and proliferate, including ribose and NADPH to synthesize
nucleotides, and glycerol-3 phosphate to produce phospholipids. The
synthesis of the latter molecules requires major amount of acetyl
moieties that are derived from beta-oxidation of fatty acids and/or fromcytosolic citrate (citrate lyase reaction) and/or from the pyruvate
dehydrogenase reaction. Given the important requirement for NADPH
in macromolecular synthesis and redox control, NADPH production in
cancer cells besides being produced through the phosphate pentose
shunt, may be signiﬁcantly sustained by cytosolic isocitrate dehydro-
genases and by the malic enzyme (see Ref. [33] for a recent review).
Therefore, many cancer cells tend to have reduced oxphos in the
mitochondria due to either or both reduced ﬂux within the tricarboxylic
acid cycle and/or respiration (Fig. 1). The latter being also caused by
reduced oxygen availability, a typical condition of solid tumours, that
will be discussed below.
Of particular relevance in the study of the metabolic changes
occurring in cancer cells, is the role of hexokinase II. This enzyme is
greatly up-regulated in many tumours being its gene promoter
sensitive to typical tumour markers such as HIF-1 and P53 [30]. It
plays a pivotal role in both the bioenergetic metabolism and the
biosynthesis of required molecules for cancer cells proliferation.
Hexokinase II phosphorylates glucose using ATP synthesized by the
mitochondrial oxphos and it releases the product ADP in close
proximity of the adenine nucleotide translocator (ANT) to favour ATP
re-synthesis within the matrix (Fig. 1). Obviously, the expression
level, the location, the substrate afﬁnity, and the kinetics of the
enzyme are crucial to the balancing of the glucose fate, to either
allowing intermediates of the glucose oxidation pathway towards
required metabolites for tumour growth or coupling cytoplasmic
glycolysis with further oxidation of pyruvate through the TCA cycle,
that is strictly linked to oxphos. This might be possible if the
mitochondrial-bound hexokinase activity is reduced and/or if it limits
ADP availability to the mitochondrial matrix, to inhibit the TCA cycle
and oxphos. However, the mechanism is still elusive, although it has
been shown that elevated oncogene kinase signaling favours the
binding of the enzyme to the voltage-dependent anion channel
(VDAC) by AKT-dependent phosphorylation [34] (Fig. 2). VDAC is a
protein complex of the outer mitochondrial membrane which is in
close proximity of ANT that exchanges ADP for ATP through the inner
mitochondrial membrane [35]. However, the enzyme may also be
detached from the mitochondrial membrane, to be redistributed to
the cytosol, through the catalytic action of sirtuin-3 that deacylates
cyclophilin D, a protein of the inner mitochondrial membrane
required for binding hexokinase II to VDAC (Fig. 2) [36]. Removing
hexokinase from the mitochondrial membrane has also another
important consequence in cancer cells: whatever mechanism its
removal activates, apoptosis is induced [37,38]. These observations
indicate hexokinase II as an important tool used by cancer cells to
survive and proliferate under even adverse conditions, including
hypoxia, but it may result an interesting target to hit in order to
induce cells cytotoxicity. Indeed, a stable RNA interference of
hexokinase II gene showed enhanced apoptosis indices and inhibited
growth of human colon cancer cells; in accordance in vivo experi-
ments indicated a decreased tumour growth [39].
In addition to having to adopt the aerobic glycolysis, many cancer
cells present a number of other metabolic changes that in the
mitochondria include: decreased oxidation of substrates (mostly
NADH-linked), altered expression and activity of respiratory chain
subunits, overproduction of ROS, mitochondrial DNA (mtDNA)
mutations, impaired both respiratory chain complexes and ATP
synthase organization within the inner mitochondrial membrane,
and altered control of apoptosis.
3. Oxidative phosphorylation peculiarities in cancer cells
3.1. Respiratory chain complexes and ATP synthase
Beyond transcriptional control of metabolic enzyme expression by
oncogenes and tumour suppressors, it is becoming evident that
environmental conditions affect the mitochondrial energy
Fig. 1. Schematic illustration of mitochondrial metabolism and metabolic reprogramming in tumours. In normal cells (A), glucose is phosphorylated by HK-I, then the major part is
degraded via glycolysis to pyruvate, which prevalently enters the mitochondria, it is decarboxylated and oxidized by PDH to acetyl-coenzyme A, which enters the TCA cycle where
the two carbons are completely oxidized to CO2 whereas hydrogen atoms reduce NAD+ and FAD, which feed the respiratory chain (turquoise). Minor part of glycolytic G-6P is
diverted to produce ribose 5-phosphate (R-5P) and NADPH, that will be used to synthesize nucleotides, whereas triose phosphates in minimal part will be used to synthesize lipids
and phospholipids with the contribution of NADPH and acetyl-coenzyme A. Amino acids, including glutamine (Gln) will follow the physiological turnover of the proteins, in minimal
part will be used to synthesize the nucleotides bases, and the excess after deamination will be used to produce energy. In the mitochondria inner membranes are located the
respiratory chain complexes and the ATP synthase (turquoise), which phosphorylates ADP releasing ATP, that in turn is carried to the cytosol by ANT (green) in exchange for ADP.
About 1–2% O2 uptaken by the mitochondria is reduced to superoxide anion radical and ROS. In cancer cells (B), where anabolism is enhanced, glucose is mostly phosphorylated by
HK-II (red), which is up-regulated and has an easy access to ATP being more strictly bound to the mitochondria. Its product, G-6P, is only in part oxidized to pyruvate. This, in turn, is
mostly reduced to lactate being both LDH and PDH kinase up-regulated. A signiﬁcant part of G-6P is used to synthesize nucleotides that also require amino acids and glutamine.
Citrate in part is diverted from the TCA cycle to the cytosol, where it is a substrate of citrate lyase, which supplies acetyl-coenzyme A for lipid and phospholipid synthesis that also
requires NADPH. As indicated, ROS levels in many cancer cells increase.
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mitochondrial dysfunction is one of the more recurrent features of
cancer cells, as reported at microscopic, molecular, biochemical, and
genetic level [7,40,41]. Although cancer cells under several conditions,
including hypoxia, oncogene activation, and mDNA mutation, may
substantially differ in their ability to use oxygen, only few reports
have been able to identify a strict association between metabolic
changes and mitochondrial complexes composition and activity. In
renal oncocytomas [42] and in lung epidermoid carcinoma [43], the
NADH dehydrogenase activity and protein content of Complex I were
found to be strongly depressed; subsequently, in a thyroid oncocy-
toma cell line [44] a similar decrease of Complex I activity wasascribed to a speciﬁc mutation in the ND1 gene of mitochondrial DNA.
However, among the respiratory chain complexes, signiﬁcant de-
crease of the only Complex I content and activity was found in K-ras
transformed cells in our laboratory [45], and could not be ascribed to
mtDNAmutations, but rather, based on microarray analysis of oxphos
genes, we proposed that a combination of genetic (low transcription
of some genes) and biochemical events (assembly factors deﬁciency,
disorganization of structured supercomplexes, and ROS-induced
structural damage) might cause the Complex I defects.
In some hereditary tumours (renal cell carcinomas) a correlation
has been identiﬁed between mitochondrial dysfunctions and content
of oxphos complexes [46]. For instance, the low content of ATP
NUCLEUS
VDAC
ANT
HK-II
PTP
UCP2
Glucose
PyrLactate
Pyr
Mal
NAD(P)H
AA TCAc
FA
STAT3 RAS
ROS
Bcl-2
HIF
NADH
FADH2
mtDNA
KG
Bcl-xl
mTOR
LDH
SIRT-3
AKT
CyP-D
AA
Gln
ME
Fig. 2. Schematic illustration of the main mitochondrial changes frequently occurring in cancer cells. The reprogramming of mitochondrial metabolism in many cancer cells
comprises reduced pyruvate oxidation by PDH followed by the TCA cycle, increased anaplerotic feeding of the same cycle, mostly from Gln, whose entry in the mitochondrial matrix
is facilitated by UCP2 up-regulation. This increases also the free fatty acids uptake by mitochondria, therefore β-oxidation is pushed to produce acetyl-coenzyme A, whose oxidation
contributes to ATP production. In cancer cells many signals can converge on the mitochondrion to regulate the mitochondrial membrane permeability, which may respond by
elevating the MPTP (PTP) threshold, with consequent enhancement of apoptosis resistance. ROS belong to this class of molecules since it can enhance Bcl2 and may induce DNA
mutations. Dotted lines indicate regulation; solid lines indicate reaction(s).
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chromophilic tumours, seems to indicate that the mitochondria are in
an inefﬁcient structural and functional state [46]. However, it cannot
be excluded that, in some cases, the structural alteration of ATP
synthase may offer a functional advantage to cells exhibiting a
deﬁcient respiratory chain for instance to preserve the transmem-
brane electrical potential (Δψm) [47]. It is likely that low levels of ATP
synthasesmay play a signiﬁcant role in cancer cell metabolism since it
has been reported that in tumours from many different tissues,
carcinogenesis speciﬁcally affects the expression of F1-ATPase β
subunit, suggesting alterations in the mechanisms that control
mitochondrial differentiation (see for a detailed review [48]). What
it seems intriguing is the overexpression of the inhibitor protein, IF1,
reported in hepatocellular carcinomas [49,50] and in Yoshida sarcoma
[51]. Normally, this protein binds to the F1 domain of the ATP synthase
inhibiting its activity [52], and it is believed to limit the ATP hydrolysis
occurring in themitochondria of hypoxic cells, avoiding ATP depletion
and maintaining Δψm to a level capable to avoid the induction of cell
death [5]. But why is its expression in cancer cells enhanced in front of
a reduced F1-ATPase β subunit?
The ﬁrst possibility is that IF1 has a function similar to that in
normal cells, simply avoiding excessive ATP hydrolysis therefore
limiting Δψm enhancement, but in cancer cells this is unlikely due to
both the reduced level of ATP synthase [46] and the high afﬁnity of IF1
for the enzyme. A second possibility might be that cancer cells need
strongly reduced oxphos to adapt their metabolism and acquire a
selective growth advantage under adverse environmental conditions
such as hypoxia, as it has been experimentally shown [53]. Finally, IF1
might contribute to the saving of the inner mitochondrial membrane
structure since it has been reported its capability to stabilize
oligomers of ATP synthase, which in turn can determine cristae
shapes [54]. In this regard, recent experimental evidence has shed
some light on a critical role of mitochondrial morphology in the
control of important mitochondrial functions including apoptosis [55]and oxidative phosphorylation [56]. In particular, dysregulated
mitochondrial fusion and ﬁssion events can now be regarded as
playing a role in cancer onset and progression [57]. Accordingly,
mitochondria-shaping proteins seem to be an appealing target to
modulate the mitochondrial phase of apoptosis in cancer cells. In fact,
several cancer tissues: breast, head-and-neck, liver, ovarian, pancre-
atic, prostate, renal, skin, and testis, showed a pattern suggestive of
enlarged mitochondria resulting from atypical fusion [58].
As already mentioned in the above paragraphs, mitochondrial
metabolism is reprogrammed in many tumours with a high
variability. However, relatively few reports focus on the main
functional parameters of mitochondria, including the membrane
potential and intrinsic proteins controlling it, the coupling of
respiration to ATP synthesis, and the ATP synthesis rate itself. Since
both mtDNA mutations and oncogene products modify cells bioen-
ergetics, which is strictly associated with ROS generation and
apoptosis, analysis of the mitochondrial main functional parameters
might provide useful information for both cancer diagnosis and
therapeutical approaches.
3.2. Mitochondrial membrane potential in cancer cells
Critical mitochondrial functions, including ATP synthesis, ion
homeostasis, metabolites transport, ROS production, and cell death
are highly dependent on the electrochemical transmembrane poten-
tial, a physico-chemical parameter consisting of two components, the
major of which being the transmembrane electrical potential (Δψm)
(see for a recent review [59]). In normal cells, under normoxic
conditions, Δψm is build up by the respiratory chain and is mainly
used to drive ATP synthesis, whereas in anoxia or severe hypoxia it is
generated by the hydrolytic activity of the ATP synthase complex and
by the electrogenic transport of ATP in exchange for ADP from the
cytosol to the matrix, operated by the adenine nucleotide translocator
[17]. Dissipation of the mitochondrial membrane potential (proton
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from ADP phosphorylation by the ATP synthase complex. Proton leak
functions as a regulator of mitochondrial ROS production and its
modulation by uncoupling proteins may be involved in pathophys-
iology, including tumours. In addition, Δψm plays a role in the control
of the mitochondrial permeability transition pore (MPTP), that might
be critical in determining reduced sensitivity to stress stimuli that
were described in neoplastic transformation [60], implying that
dysregulation of pore opening might be a strategy used by tumour
cells to escape death. Indeed, it has recently been reported that ERK is
constitutively activated in the mitochondria of several cancer cell
types, where it inhibits glycogen synthase kinase-3-dependent
phosphorylation of CyP-D and renders these cells more refractory to
pore opening and to the ensuing cell death [61].
It is worth mentioning a second protein of the inner mitochondrial
membrane, the uncoupling protein, UCP2 (Fig. 2), which contributes to
regulate Δψm. Indeed, recent observations evidenced its overexpression
in various chemoresistent cancer cell lines and in primary human colon
cancer. This overexpression was associated with an increased apoptotic
threshold [62]. Moreover, UCP2 has been reported to be involved in
metabolic reprogramming of cells, and appeared necessary for efﬁcient
oxidation of glutamine [63]. On the whole, these results led to
hypothesize an important role of the uncoupling protein in the
molecular mechanism at the basis of the Warburg effect, that suppose
a reduced Δψm-dependent entry of pyruvate into the mitochondria
accompanied by enhanced fatty acid oxidation and high oxygen
consumption (see for a review [64]). However, in breast cancer Sastre-
Serra et al. [65] suggested that estrogens by down-regulating UCPs,
increase mitochondrial Δψm, that in turn enhances ROS production,
therefore increasing tumorigenicity. While the two above points of view
concur to support increased tumorigenicity, the mechanisms at the basis
of the phenomenon appear on the opposite of the other. Therefore,
although promising for the multiplicity of metabolic effects in which
UCPs play a role (see for a recent review [66]), at present it seems that
much more work is needed to clarify how UCPs are related to cancer.
A novel intriguing hypothesis has recently been put forward
regarding effectors of mitochondrial function in tumours. Wegrzyn J
et al. [67] demonstrated the location of the transcription factor STAT3
within the mitochondria and its capability to modulate respiration by
regulating the activity of Complexes I and II, and Gough et al. [68]
reported that human ras oncoproteins depend on mitochondrial
STAT3 for full transforming potential, and that cancer cells expressing
STAT3 have increased both Δψm and lactate dehydrogenase level,
typical hallmarks of malignant transformation (Fig. 2). A similar
increase of Δψm was recently demonstrated in K-ras transformed
ﬁbroblasts [45]. In this study, the increased Δψm was somehow
unexpected since the cells had shown a substantial decrease of
NADH-linked substrate respiration rate due to a compatible reduced
Complex I activity with respect to normal ﬁbroblasts. The authors
associated the reduced activity of the enzyme to its peculiar low level
in the extract of the cells that was conﬁrmed by oxphos nuclear gene
expression analysis. This signiﬁcant and peculiar reduction of
Complex I activity relative to other respiratory chain complexes, is
recurrent in a number of cancer cells of different origin [42,44,45,69].
Signiﬁcantly, all those studies evidenced an overproduction of ROS in
cancer cells, which was consistent with the mechanisms proposed by
Lenaz et al. [70] who suggested that whatever factor (i.e. genetic or
environmental) initiate the pathway, if Complex I is altered, it does
not associate with Complex III in supercomplexes, consequently it
does not channel correctly electrons from NADH through coenzyme Q
to Complex III redox centres, determining ROS overproduction. This,
in turn, enhances respiratory chain complexes alteration resulting in
further ROS production, thus establishing a vicious cycle of oxidative
stress and energy depletion, which can contribute to further
damaging cells pathways and structures with consequent tumour
progression and metastasis [69].Concerning association of oxphos complexes in supramolecular
complexes within the mitochondrial membrane, of notice is the
organization of ATP synthase complexes in K-ras transformed cells.
Fig. 3 exhibits a typical pattern obtained from 2D electrophoresis
analysis of normal and transformed ﬁbroblasts, showing a strong
reduction of ATP synthase oligomers in the transformed cells, which
suggests a changed organization of the mitochondrial cristae. Further
studies are in due course in our laboratory to verify this hypothesis
and to evaluate whether the natural inhibitor protein of the ATP
synthase complex [52] plays a role in the induction of this
phenomenon, as hypothesized by Campanella et al. [71]. If this is
the case, a novel possible target of interest in developing therapies for
treatment of certain tumours might be considered.
3.3. Mutation of nuclear genes encoding mitochondrial proteins
Mutations of nuclear encoded mitochondrial proteins have been
linked to cancer. Here we just mention mutations in two enzymes of
the TCA cycle: succinate dehydrogenase (SDH) and fumarate
hydratase (FH), that were associated with phaeochromocytomas
and renal cancer, respectively (see for an extensive review [72]). In
both conditions an accumulation of TCA cycle intermediates succinate
and fumarate, respectively, was observed, and this accumulation was
shown capable to stabilize HIF-1α, supporting the conclusions of
Selak et al. [73] who demonstrated the inhibiting effect of succinate on
the HIF-1α prolyl hydroxylase, a crucial enzyme for HIF-1α removal,
that resulted in the stabilization of HIF-1. A mutation in a third TCA
cycle enzyme, isocitrate dehydrogenase, has recently been described
in the majority of grade II and grade III gliomas and secondary
glioblastomas [74]. The single amino acid change (Arg-132 to His) in
the enzyme results in loss of the enzyme's ability to catalyze
conversion of isocitrate to α-ketoglutarate, and it determines the
formation and accumulation of 2-hydroxyglutarate, which has been
shown to be an onco-metabolite. Other mutations have been reported
in nuclear genes encoding proteins being relatedwith both replication
of mtDNA and assembly of respiratory chain complexes. Indeed, 63%
of the breast tumours examined by Singh et al. [75] harbored
mutations in the polymerase γ gene, resulting in severe mtDNA
depletion and oxphos impairment.
3.4. Mitochondrial DNA mutation and cancer
In the last decade, there has been considerable interest in the
possibility that mtDNA mutations might predispose or at least play a
role in common diseases, including human cancer. Accordingly, many
reports are being focused onmitochondrial DNAmutation and cancer.
Nonetheless the mechanisms responsible for the initiation and
evolution of mtDNA mutations, and their roles in the development
of cancer and disease progression still remain to be fully elucidated. It
is intriguing that, as recently reported, the high heterogeneity of
human mtDNA was found to be signiﬁcantly ampliﬁed in tumours
[76]. The ﬁrst paper consistently describing the presence of somatic
mtDNA mutations in human tumours was reported by Polyak et al.
[77]. In 7 out of 10 cell lines from patients with colorectal tumours, the
authors evidenced the occurring of homoplasmic mtDNA mutations,
which were neither found in normal colon nor in other tissues from
the same patients. Of notice is the almost absence of the mutations
effects on the mitochondrial function, a situation reported also in
another study, in which the entire mitochondrial genome sequence
from normal and leukaemic cells obtained from 24 patients with both
chronic and acute presentations were compared [78]. Incidentally, in
any of the above cases, there was no evidence of whether mtDNA
mutations themselves contributed to the development of the tumour.
However, some years later, in a very interesting study, Petros et al.
[79] found that 11–12% of all prostate cancer patients treated over the
previous 7 years at their institutional tissue resources harbored
Fig. 3. Two-dimensional analysis of mitochondrial ATP synthase (F1F0-ATPase) in wild-type (Top) and K-ras transformed (Bottom) ﬁbroblasts. Monomer and oligomers separation
was achieved by 1D Blue-Native electrophoresis followed by 2D SDS-PAGE. 2D gels were blotted onto the nitrocellulose membrane and then exposed to a monoclonal antibody
speciﬁc for subunit β of the F1F0-ATPase complex. In 1D, monomeric Complex I and Complex V (molecular mass about 1000 and 600 kDa, respecively), dimeric Complex III
(molecular mass about 500 kDa), and F1 (molecular mass about 400 kDa), the catalytic domain of the ATP synthase complex are indicated. Arrows indicate dimeric and oligomeric
F1F0-ATPases. The amount of the oligomers of the ATP synthase is higher in wild-type than in transformed cells. Moreover, the highest molecular mass oligomer is completely absent
in K-ras transformed ﬁbroblasts. Details of electrophoretic and blotting methods are reported in Ref. [45].
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observation induced the authors to evaluate whethermutant tumours
had increased tumour growth rate. Therefore, the pathogenic mtDNA
nt8993T>G mutation in the ATP6 gene [80] was introduced into PC3
prostate cancer cells through cybrids (trans-mitochondrial hybrids)
transfer. After injection in nude mice tumour growth was tested.
These experiments revealed that the average tumour volume of the
mutant PC3 cybrids was signiﬁcantly higher (7-fold) than that of
controls, and induced increased ROS generation. Therefore it could be
shown that mtDNA mutations increase tumorigenicity in animal
models of prostate cancer. Similarly, Shidara et al. [81] showed the
positive contribution of pathogenic mutations in mtDNA to the
promotion of cancer, and in addition, they demonstrated that these
mutations can effectively promote cancer growth by preventing
apoptosis. In accordance, it was recently shown that the presence of
heteroplasmic (only a fraction of the mtDNA molecules is mutated)
mutations in two genes encoding polypeptides of the respiratory
chain Complex I (ND1 subunit) and III (cytochrome b), respectively,
could result in thyroid oncocytic carcinoma [44]. Again, the authors
found a dramatic increase in ROS production, which was associated
with a concurrent dramatic activity decrease of Complex I and to a
lesser extent of Complex III, the main mitochondrial sources of ROS
[82]. Similar results have been reported by Ishikawa et al. [69], who
also showed an increase of tumorigenicity and development of
metastasis in transformed cells transfected with pathogenic mtDNA
mutations. Very recent papers report somatic mutations in the
mitochondrial genome in nearly one out of four gastric cancer
specimen and stress the potential role of those mutations in the
progression of the disease [83], whereas Kulawiec et al. [84] showed
that in some samples of breast cancer cells, mtDNA mutations were
not associated with ROS production, but constitutively activate the
PI3K/AKT pathway contributing to increased metastasis. In addition,
this pathway is strictly linked and activated in association with the
serine/threonine kinase target of rapamycin (TOR) that controls key
cellular processes such as cell survival, growth and proliferation.
Consistent with its role in cell proliferation, the mTOR pathway is
frequently hyperactivated in a number of human malignancies [85]and its TORC1 protein complex exerts a direct control of mitochon-
drial function via a complex comprising Bcl-xl and VDAC1 at the
mitochondrial outer membrane (Fig. 2) [86]. For this reason, several
mTOR inhibitors have been approved for cancer therapy, and late-
stage clinical trials are underway [87].
3.5. Hypoxia and oxidative phosphorylation in cancer cells
Tumour cells experience an extensive heterogeneity of oxygen
levels, from normoxia (around 2–4% oxygen tension), through
hypoxia, to anoxia (b0.1% oxygen tension). The growth of tumours
beyond a critical mass N1–2 mm3 is dependent on adequate blood
supply to receive nutrients and oxygen by diffusion [88]. Cells
adjacent to capillaries were found to exhibit a mean oxygen
concentration of 2%, therefore, beyond this distance, hypoxia occurs:
indeed, cells located at 200 μm displayed a mean oxygen concentra-
tion of 0.2%, which is a condition of severe hypoxia [89]. Oxygen
shortage results in hypoxia-dependent inhibition of mitochondrial
activity, mostly mediated by the hypoxia-inducible factor 1 (HIF-1)
[90,91]. More precisely, hypoxia affects structure, dynamics, and
function of the mitochondria, and in particular it has a signiﬁcant
inhibitory effect on the oxidative phosphorylation machinery, which
is the main energy supplier of cells (see Ref. [22] for a recent review).
The activation of HIF-1 occurs in the cytoplasmic region of the cell, but
the contribution of mitochondria is critical being both cells oxygen
sensors and suppliers of effectors of HIF-1α prolyl hydroxylase like
α-ketoglutarate and probably ROS, that inhibit HIF-1α removal [92].
As reported above, mitochondria can also promote HIF-1α stabiliza-
tion if the TCA ﬂux is severely inhibited with release of intermediate
molecules like succinate and fumarate into the cytosol. On the other
hand, HIF-1 can modulate mitochondrial functions through different
mechanisms, that besides metabolic reprogramming [7,22,93,94],
include alteration of mitochondrial structure and dynamics [58],
induction of microRNA-210 that decreases the cytochrome c oxidase
(COX) activity by inhibiting the gene expression of the assembly
protein COX10 [95], that also increases ROS generation. Moreover,
these stress conditions could induce the anti-apoptotic protein Bcl-2,
540 G. Solaini et al. / Biochimica et Biophysica Acta 1807 (2011) 534–542which has also been reported to regulate COX activity and
mitochondrial respiration [96] conferring resistance to cells death in
tumours (Fig. 2). This effect might be further enhanced upon severe
hypoxia conditions, since COX is also inhibited by NO, the product of
activated nitric oxide synthases [97].
The reduced respiration rate occurring in hypoxia favours the
release of ROS also by Complex III, which contribute to HIF
stabilization and induction of Bcl-2 [98]. In addition, hypoxia reduces
oxphos by inhibiting the ATP synthase complex through its natural
protein inhibitor IF1 (discussed in a previous section), which
contributes to the enhancement of the “aerobic glycolysis”, all
signatures of cancer transformation.
Interestingly, a recent study based on metabolome analysis of
colon and stomach cancer cells suggests a signiﬁcant energy
generation by the so-called fumarate respiration (i.e. fumarate rather
than molecular oxygen is used as electron acceptor) under conditions
of glucose deprivation and severe hypoxia [99].
Considering the pro-tumoral effect of hypoxia, some research
groups have investigated whether hyperoxia may be useful in cancer
therapy. For instance, Cannizzaro et al. [100] studied the effect of
exposition at high oxygen tension of two human neuroblastoma cell
lines (SK-N-SH and SK-N-DZ) and found that the treatment was able
to induce cell growth inhibition and cell cycle perturbation. In
particular, it was observed an arrest at G(2) phase, accompanied by an
alteration in the expression and localization of cyclin B1/cdk1
complex and a reduction in its activity in SK-N-SH cells. Based on a
different mechanism, hyperoxia induced apoptosis in SK-N-DZ cells
via caspase 3 activation and Poly ADP-ribose polymerase-1 (PARP)
cleavage, associated with increased pro-apoptotic Bax protein. In
addition, preliminary observations demonstrated increased ROS and
membrane lipid peroxidation in cultured U87 human glioma cells
exposed to either normobaric hyperoxia or hyperbaric hyperoxia. On
the same study, it was also shown that membrane blebbing enhanced
with increasing O2 tension, therefore suggesting a possible use of
hyperoxia to induce cells death [101]. These very preliminary
investigations seem interesting, but much more has to be known in
order to attempt therapeutic treatments of tumours by this approach.
4. Conclusions
The observations reported to date indicate that cancer cells exhibit
large varieties of metabolic changes which are associated with
alterations in the mitochondrial structure, dynamics and function,
andwith tumour growth and survival. On one hand, mitochondria can
regulate tumour growth through modulation of the TCA cycle and
oxidative phosphorylation. The altered TCA cycle provides intermedi-
ates for both macromolecular biosynthesis and regulation of tran-
scription factors such as HIF, and it allows cytosolic reductive power
enhancement. Oxphos provides signiﬁcant amounts of ATP which
varies among tumour types. On the other hand, mitochondria are
crucial in controlling redox homeostasis in the cell, inducing them to
be either resistant or sensitive to apoptosis. All these reasons locate
mitochondria at central stage to understanding the molecular basis of
tumour growth and to seeking for novel therapeutical approaches.
Due to the complexity and variability of mitochondrial roles in
cancer, careful evaluation of mitochondrial function in each cancer
type is crucial. Deeper and more integrated knowledge of mitochon-
drial mechanisms and cancer-speciﬁc mitochondrial modulating
means are expected for reducing tumorigenicity and/or improving
anticancer drugs efﬁcacy at the mitochondrial level. Although the
great variability of biochemical changes found in tumour mitochon-
dria, some highlighted peculiarities such as reduced TCA cycle ﬂux,
reduced oxphos rate, and reduced Complex I activity with respect to
tissue speciﬁc normal counterparts are more frequent. In addition,
deeper examination of supramolecular organization of the complexes
in the inner mitochondrial membrane has to be considered in relationto oxphos dysfunction. Indeed, investigations on this topic in a set of
tumour cells of different origins are currently carried out in our
laboratory. Preliminary results here reported (Fig. 3) suggest a
signiﬁcant reorganization of the mitochondrial inner membrane at
least in K-ras transformed cells.
Moreover, investigations into mechanisms of mitochondrial
metabolic changes and how critical signaling pathways interact will
uncover new therapeutic approaches in a diverse range of tumours. In
this context, developing therapies based on RNA interference: post-
transcriptional gene silencingmediated by small RNA duplexes, which
has the advantage of high speciﬁcity and potent gene silencing, will
disclose powerful weapons against tumours. The speciﬁcity of the
treatment at present seems crucial due to the interdependence of
metabolic pathways that makes very difﬁcult to have beneﬁts without
altering any other important process within the cells. However, in the
early and mid future, we might expect the developing of therapeutic
interventions based on controlling the mitochondrial pathway for
apoptosis that seem very promising. In addition, mitochondrial
targeting of ROS scavengers and compounds that interfere with the
unique biochemistry in the mitochondria are under investigation as
promising therapeutic attempts.
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